Propanc Biopharma shares rise 10.96% intraday after submitting Spain patents for resistant cancer and fibrosis treatments.

Propanc Biopharma surged 10.96% in intraday trading following the announcement of two provisional patent submissions for novel treatments targeting resistant cancer and fibrosis. The company, in collaboration with Spanish universities, filed for a foreign filing license in Spain, with plans to extend these patents to key global jurisdictions. The fibrosis-related patent marks the first expansion of its lead proenzyme therapy, PRP, into chronic diseases beyond cancer, positioning it as a potential breakthrough in fibrosis treatment. CEO James Nathanielsz highlighted the significance of these developments, emphasizing PRP’s potential to address unmet medical needs without cytotoxic effects. The planned 2026 Phase 1b First-In-Human study to determine PRP’s therapeutic dose further underscores the company’s progress toward clinical validation, fueling investor optimism about its commercial prospects.